• Puromycin Aminonucleoside: Applied Workflows in Podocyte Inj

  2026-05-09

  Puromycin aminonucleoside enables precise, reproducible induction of podocyte injury and proteinuria, making it indispensable for nephrotic syndrome research. This guide delivers stepwise experimental workflows, optimization strategies, and troubleshooting insights for maximizing translational relevance in glomerular lesion modeling.

• Applied Workflows with (-)-Epigallocatechin Gallate (EGCG)

  2026-05-08

  (-)-Epigallocatechin gallate (EGCG) stands out as a versatile bioactive for antiangiogenic, apoptosis, and antiviral research. This article details evidence-backed protocols, advanced assay applications, and optimization strategies that harness EGCG’s multifaceted potential—enabling reproducible, high-impact experimental outcomes.

• L-Ornithine in the Liver–Brain Axis: Mechanisms and Strategy

  2026-05-08

  Explore the latest mechanistic insights and translational strategies for leveraging L-Ornithine ((S)-2,5-diaminopentanoic acid) in research on ammonia detoxification, CNS-liver crosstalk, and metabolic enzyme dysfunction. Anchored by new evidence implicating ornithine accumulation in arsenic-induced neurotoxicity, this article provides actionable experimental guidance and a forward-looking vision for advancing metabolic and neurotoxicology research. Contextual product intelligence and rigorous evidence integration distinguish this discussion from standard reagent guides.

• Nanoparticle-Mediated PTEN mRNA Delivery Reverses Trastuzuma

  2026-05-07

  This study presents a nanoparticle platform for systemic delivery of PTEN mRNA to overcome trastuzumab resistance in HER2-positive breast cancer. By restoring PTEN expression and inhibiting the PI3K/Akt pathway, this approach offers a mechanistically rational strategy for combating resistance in targeted cancer therapy.

• MLN4924: Precision NEDD8-Activating Enzyme Inhibitor in Canc

  2026-05-07

  MLN4924, a potent NEDD8-activating enzyme inhibitor, enables researchers to dissect neddylation-dependent processes with unparalleled specificity in cancer models. This guide details experimental workflows, troubleshooting strategies, and translational applications, bridging new mechanistic insights with robust, reproducible assay design.

• hiPSC-Derived Intestinal Organoids in Pharmacokinetic Studie

  2026-05-06

  This study presents a streamlined protocol for generating human pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) capable of differentiating into mature enterocytes with functional cytochrome P450 activity. The findings provide a more physiologically relevant in vitro platform for pharmacokinetic and drug metabolism research, overcoming key limitations of animal and cancer cell models.

• Sulfo-NHS-Biotin: Precision Protein Labeling for Surface Pro

  2026-05-06

  Sulfo-NHS-Biotin empowers selective, rapid, and irreversible biotinylation of cell surface proteins directly in aqueous buffers, eliminating organic solvents and improving workflow efficiency. This reagent stands out for its membrane-impermeable design, which enables high-fidelity cell surface mapping, affinity capture, and quantitative proteomics with minimal background. Advanced troubleshooting and protocol insights ensure optimal results for both routine and specialized applications.

• Phosphatase Inhibitor Cocktail 2: Precision Control in Phosp

  2026-05-05

  Explore how Phosphatase Inhibitor Cocktail 2 (100X in ddH2O) revolutionizes protein phosphorylation preservation for advanced biochemical and signaling studies. Gain insights into its scientific rationale, protocol optimization, and the latest reference-backed applications.

• (S)-(+)-Dimethindene maleate: Practical Use in M2 Antagonist

  2026-05-05

  (S)-(+)-Dimethindene maleate is a selective M2 muscarinic receptor antagonist with dual H1 histamine antagonism, making it suitable for studies in autonomic regulation, cardiovascular physiology, and respiratory system function. It is not appropriate for diagnostic or clinical applications and should be used only within the boundaries of its documented selectivity and solubility properties.

• Chlorpromazine HCl: Mechanistic Leverage for Translational R

  2026-05-04

  This thought-leadership article explores Chlorpromazine HCl's evolving role as a dopamine receptor antagonist in neuropharmacology and infection biology, integrating mechanistic insights with actionable strategies for translational researchers. By synthesizing recent evidence—including the induction of ROS and autophagy in macrophages—this piece sets a new agenda for leveraging Chlorpromazine HCl in next-generation experimental workflows, emphasizing APExBIO's rigor and strategic guidance.

• Neuroligin 1 Proteolysis Links Synaptic Remodeling to Social

  2026-05-04

  This study uncovers a mechanism by which social interaction triggers α- and γ-secretase-dependent proteolysis of neuroligin 1 in the ventral hippocampus, generating intracellular fragments that are essential for the maintenance of social memory. The findings connect extracellular cues to intracellular signaling and synaptic plasticity, with implications for understanding memory deficits in neuropsychiatric disorders.

• Phenothiazines Boost Macrophage Antibacterial Activity via R

  2026-05-03

  The study reveals that phenothiazines, a class of dopamine receptor antagonists, enhance macrophage antibacterial function by inducing reactive oxygen species (ROS) production and autophagy. These findings have significant implications for host-directed therapies against intracellular bacterial infections, offering a novel approach in the context of rising antibiotic resistance.

• DHT in Translational Research: From AR Signaling to Resistan

  2026-05-02

  This article explores how Dihydrotestosterone (DHT) enables advanced dissection of androgen receptor (AR) and EGFR/ERBB2 signaling in cancer and neuromuscular disease models. By integrating recent mechanistic insights—such as the role of ECM1 in anti-androgen resistance in bone metastatic prostate cancer—it provides translational researchers with strategic guidance for experimental design, assay optimization, and future therapeutic targeting. The narrative demonstrates how APExBIO’s DHT product supports precision research workflows and surpasses conventional product discussions by bridging mechanistic understanding to actionable translational value.

• TP53 and DHODH Inhibition: New Insights in Nasopharyngeal Ca

  2026-05-01

  Dong et al. reveal that targeting dihydroorotate dehydrogenase (DHODH) suppresses nasopharyngeal carcinoma (NPC) cell growth through TP53-dependent mechanisms. This work provides the first comprehensive evidence for nucleic acid metabolism reprogramming as a therapeutic vulnerability in NPC, highlighting the potential of DHODH inhibition to improve outcomes in tumors with intact TP53.

• IPA-3: Workflow-Driven Pak1 Inhibition for Advanced Cell Ass

  2026-05-01

  IPA-3 (1-[(2-hydroxynaphthalen-1-yl)disulfanyl]naphthalen-2-ol) empowers researchers to dissect Pak1 signaling with high selectivity and reproducibility. Explore how this non-ATP-competitive inhibitor from APExBIO optimizes kinase assays, cell-based studies, and translational research—from cancer biology to neuroinflammation.

14599 records 1/974 page Next 12345 下5页 Last page